Friday, July 31

Browsing: TET2

Research

Rewiring of de novo serine synthesis supports tumorigenesis under deficiency of TET2

By NewsCancerJune 26, 20260

Wu X, Zhang Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017;18:517–34.Article CAS PubMed Google Scholar …

Research

One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol

By NewsCancerApril 5, 20260

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping myelodysplastic and myeloproliferative features [1]. TET2 is…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

Browsing: TET2

Rewiring of de novo serine synthesis supports tumorigenesis under deficiency of TET2

One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol

Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Latest Post

Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

Subscribe to Updates

What's Hot

Browsing: TET2